ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01% ophthalmic solution
Drug: bimatoprost 0.03% ophthalmic solution

First Posted Date: 2011-02-18

Last Posted Date: 2018-09-17

Lead Sponsor: Allergan

Target Recruit Count: 806

Registration Number: NCT01298700

Locations: 🇮🇱
Glaucoma Service The Rabin Medical Center, Petach Tiqva, Israel
🇮🇱
Kaplan Medical Center, Rehovot, Israel
🇧🇪
UZ Leuven, Leuven, Belgium

and more 47 locations

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: carboxymethylcellulose sodium based New Eye Drop Formulation 2
Drug: carboxymethylcellulose sodium based Eye Drops
Drug: carboxymethylcellulose sodium based New Eye Drop Formulation 1

First Posted Date: 2011-02-11

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 305

Registration Number: NCT01294384

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: AGN-210669
Drug: bimatoprost vehicle
Drug: bimatoprost

First Posted Date: 2011-02-08

Last Posted Date: 2013-11-06

Lead Sponsor: Allergan

Target Recruit Count: 125

Registration Number: NCT01291108

Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 3

Withdrawn

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution

First Posted Date: 2011-01-26

Last Posted Date: 2013-07-18

Lead Sponsor: Allergan

Registration Number: NCT01284166

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

Phase 4

Completed

Conditions: Glabellar Lines

Interventions: Biological: botulinum toxin type A

First Posted Date: 2011-01-06

Last Posted Date: 2019-01-29

Lead Sponsor: Allergan

Target Recruit Count: 224

Registration Number: NCT01271452

Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal
Conjunctivitis, Allergic

Interventions: Drug: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution
Drug: olopatadine hydrochloride 0.1% ophthalmic solution

First Posted Date: 2010-12-10

Last Posted Date: 2012-01-25

Lead Sponsor: Allergan

Target Recruit Count: 129

Registration Number: NCT01258309

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: travoprost ophthalmic solution 0.004%
Drug: latanoprost ophthalmic solution 0.005%
Drug: bimatoprost ophthalmic solution 0.01%

First Posted Date: 2010-12-06

Last Posted Date: 2012-11-07

Lead Sponsor: Allergan

Target Recruit Count: 164

Registration Number: NCT01253902

Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment Scale for Assessment of Overall Eyelash Prominence

Completed

Conditions: Healthy Volunteers

First Posted Date: 2010-12-02

Last Posted Date: 2012-09-28

Lead Sponsor: Allergan

Target Recruit Count: 68

Registration Number: NCT01252147

Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

Phase 4

Completed

Conditions: Glaucoma, Open-Angle

Interventions: Drug: latanoprost 0.005% ophthalmic solution
Drug: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution

First Posted Date: 2010-11-18

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 81

Registration Number: NCT01243567

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

First Posted Date: 2010-11-16

Last Posted Date: 2014-09-10

Lead Sponsor: Allergan

Target Recruit Count: 192

Registration Number: NCT01241240

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy